Erasca

The Global KRAS Inhibitor Market is projected to grow from US$ 108.1 million in 2023 to US$ 186.4 million by 2033, driven by targeted cancer therapies and rising interest in KRAS mutations. North America leads with a 42.3% market share, while lung cancer dominates the cancer type segment. Recent FDA approvals and clinical trial successes, such as Nested Therapeutics' novel KRAS inhibitor, highlight the market's potential. High development costs and macroeconomic factors pose challenges, but growing cancer prevalence and rising collaborations offer opportunities.

Erasca announces positive Phase 1b SEACRAFT-1 data for naporafenib plus trametinib in NRASm melanoma, supporting ongoing Phase 3 SEACRAFT-2 trial. SEACRAFT-2 aligns with US and European regulatory paths, with Stage 1 randomized data expected in 2025. The company also reports rapid progress in its RAS targeting franchise, with planned IND submissions on track.

Early switch to atezolizumab after vemurafenib plus cobimetinib in BRAF V600-positive melanoma showed improved OS at 4 and 5 years in the ImmunoCobiVem trial, but not statistically significant. Rapid progression after switch to immune checkpoint inhibition was observed in some patients.

FDA approves Travere Therapeutics’ Filspari (sparsentan) for IgA nephropathy, the first non-immunosuppressive treatment to significantly slow kidney function decline. Based on the PROJECT study, Filspari outperformed irbesartan in preserving kidney function over two years. Common adverse events include hyperkalemia and hypotension.